Published in
Bentham Science Publishers, Letters in Drug Design & Discovery, 5(6), p. 337-344
DOI: 10.2174/1570180810906050337
Links
Tools
Discovery of Novel CYP17 Inhibitors for the Treatment of Prostate Cancer with Structure-Based Drug Design
Journal article published in 2009 by
Muhuttin Emre Özdemir 
,
Şule Özdaş,
Pelin Armutlu,
Muhuttin Ozdemir,
Halil Kavakli,
Sule Ozdas,
Ibrahim Kavakli,
Metin Türkay
,
Şule Özdaş,
Pelin Armutlu,
Muhuttin Ozdemir,
Halil Kavakli,
Sule Ozdas,
Ibrahim Kavakli,
Metin Türkay
This paper is available in a repository.
Full text: Download
Published version:
archiving forbidden
Data provided by 
Abstract
It has been shown that prostate cancer is associated with elevated androgen biosynthesis; therefore, inhibiting the activity of Cytochrome P450 17 (CYP17) may prevent progression of prostate cancer. In this study we identified, us-ing in silico and experimental methods, two novel steroidal and non-steroidal lead compounds that inhibit the activity CYP17.